Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29316784 | 1.00 | HRH3 (0.42) | HRH3KCNH2CYP2D6EPHX2 | |
| SCHEMBL29330604 | 0.88 | HRH3 (0.38) | HRH3KCNH2CYP2D6EPHX2 | |
| SCHEMBL29330618 | 0.86 | HSD11B1 (0.39) | — | |
| SCHEMBL26746322 | 0.86 | HSD11B1 (0.39) | — | |
| SCHEMBL29316808 | 0.78 | HSD11B1 (0.45) | HRH3KCNH2CYP2D6 | |
| SCHEMBL26706122 | 0.78 | HSD11B1 (0.45) | HRH3KCNH2CYP2D6 | |
| SCHEMBL26746728 | 0.78 | HSD11B1 (0.45) | HRH3KCNH2CYP2D6 | |
| SCHEMBL29316801 | 0.78 | NAMPT (0.42) | HRH3KCNH2CYP2D6 | |
| SCHEMBL26746724 | 0.78 | NAMPT (0.42) | HRH3KCNH2CYP2D6 | |
| SCHEMBL26742027 | 0.76 | TPSAB1 (0.44) | HRH3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | HRH3 4026/4885KCNH2 2357/4885CYP2D6 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.